--- title: "Akari Therapeutics Plc (AKTX) news: going concern and offering" url: "https://aibio.space/companies/akari-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AKTX going concern, offering, Nasdaq notice and merger news: Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment." --- AKTX Akari Therapeutics Plc NASDAQ · United States # Akari Therapeutics Plc (AKTX) news AKTX going concern, offering and Nasdaq notice news Distress · 2026-05-18 ## [Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment](https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/) Akari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph. ## Latest Akari Therapeutics Plc news 1. 2025-11-26 Listings [Akari Therapeutics gets Nasdaq minimum bid price deficiency notice, has until May 25, 2026](https://aibio.space/news/akari-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Nasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning. 2. 2025-03-31 Distress [Akari Therapeutics delays 2024 annual report over merger accounting](https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/) The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension. 3. 2024-11-08 Mergers [Akari Therapeutics shareholders approve share issuance for Peak Bio merger](https://aibio.space/news/akari-therapeutics-shareholders-approve-share-issuance-peak-bio-merger/) About 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency. ## Akari Therapeutics Plc at a glance - **Ticker**: AKTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $7.7 million ### Related companies - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) NASDAQ: DYN - [Apnimed](https://aibio.space/companies/apnimed/) NASDAQ: APMD - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [PureTech Health](https://aibio.space/companies/puretech-health/) LSE: PRTC - [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) AMEX: APUS - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) NASDAQ: ELOX ### Also on NASDAQ - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX - [Travere Therapeutics](https://aibio.space/companies/travere-therapeutics/) TVTX - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NTHI - [Scinai Immunotherapeutics](https://aibio.space/companies/scinai-immunotherapeutics/) SCNI - [AbCellera Biologics](https://aibio.space/companies/abcellera-biologics/) ABCL - [GRI Bio](https://aibio.space/companies/gri-bio/) GRI ## What Akari Therapeutics Plc does Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel proprietary payloads. Its lead payload, PH1, modulates the spliceosome, a complex cellular machinery that converts pre-RNA into spliced RNA, and the company says PH1 causes cancer cell death and generates neoantigen proteins that activate innate and adaptive immune systems. The company says PH1 has been demonstrated to be active against metastatic prostate cancer cells driven by AR-v7. Its lead ADC candidate, AKTX-101, targets the Trop-2 receptor on cancer cells and uses a proprietary linker to deliver PH1 directly into the tumor. The company has initiated IND-enabling studies for AKTX-101, with a goal of starting a first-in-human Phase 1 trial by late 2026 or early 2027. It is also advancing AKTX-102, an ADC against CEACAM5, a target the company says is relevant in pancreatic, colon, stomach, esophageal and lung cancers. The company notes that the PH1 platform can generate ADC candidates against different cancer antigen targets. | Product or program | What it is | Stage | |---|---|---| | PH1 payload | Novel RNA splicing modulating payload for ADC candidates | | | AKTX-101 | Trop-2 targeted ADC carrying the PH1 payload | IND-enabling studies; Phase 1 targeted for late 2026 or early 2027 | | AKTX-102 | CEACAM5 targeted ADC | | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/form10-k.htm). ## Akari Therapeutics Plc annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | | Net income (loss) | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | [-$19.8 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | | Cash from operations | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | [-$12.6 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | | Cash and equivalents | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1541157/000149315226037730/) | [$0](https://www.sec.gov/Archives/edgar/data/1541157/000149315226013664/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Negative view 2026-10-28 [Akari's cash lasts about nine months, and its latest filing flags going concern doubt](https://aibio.space/analysis/akari-cash-lasts-about-nine-months-latest-filing-flags/) Akari had $7.7 million at June 30, 2026. Our arithmetic gives about nine months, the company says December 2026, and its lead drug is not yet in the clinic. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Akari Therapeutics Plc Has Akari Therapeutics Plc issued a going-concern warning? Our latest story on this, dated May 18, 2026: "Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/). Has Akari Therapeutics Plc raised money recently? Our latest story on this, dated May 18, 2026: "Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/). Has Akari Therapeutics Plc received a Nasdaq deficiency notice? Our latest story on this, dated Nov 26, 2025: "Akari Therapeutics gets Nasdaq minimum bid price deficiency notice, has until May 25, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akari-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). Is Akari Therapeutics Plc involved in a merger or acquisition? Our latest story on this, dated Mar 31, 2025: "Akari Therapeutics delays 2024 annual report over merger accounting". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/). What is the ticker symbol of Akari Therapeutics Plc? Akari Therapeutics Plc trades under the ticker AKTX on NASDAQ. Where is Akari Therapeutics Plc listed? Akari Therapeutics Plc is listed on NASDAQ. What is the SEC CIK of Akari Therapeutics Plc? The SEC Central Index Key (CIK) for Akari Therapeutics Plc is 1541157. Its filings are on SEC EDGAR. How many shares does Akari Therapeutics Plc have outstanding? 155,758,529,533 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Akari Therapeutics Plc listed under? Our directory records Akari Therapeutics Plc under United States. What does Akari Therapeutics Plc do? Our directory classifies Akari Therapeutics Plc as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Akari Therapeutics Plc? The ISIN recorded for Akari Therapeutics Plc is US00972G4055. Does aibio.space cover Akari Therapeutics Plc? aibio.space lists Akari Therapeutics Plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Akari Therapeutics Plc incorporated? SEC records list its state or country of incorporation as X0. What does Akari Therapeutics Plc develop? Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel proprietary payloads. Its lead payload, PH1, modulates the spliceosome, a complex cellular machinery that converts pre-RNA into spliced RNA, and the company says PH1 causes cancer cell death and generates neoantigen proteins that activate innate and adaptive immune systems. What is PH1 payload from Akari Therapeutics Plc? PH1 payload: Novel RNA splicing modulating payload for ADC candidates Stage: not stated in text. ## Investor discussion: Akari Therapeutics Plc Members talk about Akari Therapeutics Plc (AKTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Akari Therapeutics Plc, newest first. Each line links the filing it comes from. 1. 2026-06-26 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226030341/form8-k.htm) 2. 2026-05-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/form8-k.htm) 3. 2026-05-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226024230/formnt10-q.htm) 4. 2026-05-08 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226022019/forms-1.htm) 5. 2026-03-17 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/ex99-1.htm) 6. 2026-01-23 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315226003458/forms-1.htm) 7. 2025-11-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315225025177/form8-k.htm) 8. 2025-10-15 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000149315225018091/form8-k.htm) 9. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1541157/000095017025047872/nt_10k_december_31_2024.htm) 10. 2024-11-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1541157/000095017024127569/aktx_nt_10-q_09.30.2024.htm) 11. 2024-11-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.01,3.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/aktx-ex99_1.htm) 12. 2024-11-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/aktx-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AKTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-AKTX/). ## SEC filings and registration - **SEC name**: Akari Therapeutics Plc - **CIK**: 1541157 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AKTX (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 401 EAST JACKSON STREET, TAMPA, FL, 33602 - **Phone**: (929) 274-7510 - **Shares outstanding**: 155,758,529,533 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Celsus Therapeutics Plc.; Morria Biopharmaceuticals PLC ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1541157/000149315226045371/formdef14a.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1541157/000149315226045364/form8-k.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/form8-k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1541157/000149315226037730/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1541157/000149315226031972/form8-k.htm) filed 2026-07-02 - [S-3](https://www.sec.gov/Archives/edgar/data/1541157/000149315226031967/forms-3.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1541157/000149315226030341/form8-k.htm) filed 2026-06-26 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1541157/000149315226027279/formdef14a.htm) filed 2026-06-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001541157), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Akari Therapeutics Plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AKTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Akari Therapeutics Plc - **Ticker**: AKTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00972G4055 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AKTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/akari-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Akari Therapeutics Plc (AKTX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/akari-therapeutics/